The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000.
In vitro susceptibilities to meropenem and comparators of Acinetobacter strains isolated from serious infections in 37 European hospital centers participating in the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program (1997-2000) were tested. There were 635 Acinetobacter strains collected: 490 A. baumannii; 51 A. calcoaceticus var. lwoffii; and 94 other Acinetobacter strains. Overall, meropenem and imipenem were the most effective agents tested. Resistance to the antimicrobials was: 14%, meropenem; 16%, imipenem; 39%, piperacillin-tazobactam; 41%, tobramycin; 45%, ceftazidime; and 53%, ciprofloxacin. Thus, the carbapenems have useful activity against Acinetobacter spp. and represent a viable choice for treating infections caused by these organisms.
Turner
P J
PJ
Antibiotic Development and Technical Support Group, AstraZeneca, Alderley House, Alderley Park, Macclesfield, Cheshire, SK10 4TF, UK. philip.turner@astrazeneca.com
Greenhalgh
J M
JM
D000150:Acinetobacter / Q000187:drug effects*; D000151:Acinetobacter Infections / Q000188:drug therapy*; D040981:Acinetobacter baumannii / Q000187:drug effects; D016954:Acinetobacter calcoaceticus / Q000187:drug effects; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology; D024881:Drug Resistance, Bacterial / Q000502:physiology*; D005060:Europe; D006801:Humans; D000077731:Meropenem; D013845:Thienamycins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D000077731:Meropenem